Literature DB >> 2942623

Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids.

K Borner, H Lode, G Höffken, C Prinzing, P Glatzel, R Wiley.   

Abstract

Two column liquid chromatographic (HPLC) methods for the determination of ciprofloxacin and three metabolites are described. Both use reversed phase chromatography, the stationary phase being Nucleosil 5C18. Method A separates ciprofloxacin, metabolite M1 and another metabolite of unknown structure using fluorometric detection. Method B allows the determinations of metabolite M3 (oxo-ciprofloxacin) in urine by UV absorption. Serum was deproteinised with acetonitrile. Urine was diluted with buffer solution. The detection limit of ciprofloxacin was 0.010 mg/l serum and 0.2 mg/l urine and for the metabolite M3, 1 mg/l urine. Within-batch precision (coefficient of variation) for ciprofloxacin in serum was 0.8 to 2.4% and between-batch precision 4.8 to 9.3%. In urine within-batch precision was 1.7 to 2.1% and between-batch precision 2.4 to 7.2%. Recovery rates of ciprofloxacin from three groups of spiked sera was 94.5 +/- 2.6%, 97.2 +/- 1.1% and 95.0 +/- 1.8% and from urine 99.6%. Results obtained by HPLC (method A) were compared with those from a standard microbiological assay by means of bivariate regression analysis. In 12 subsets of data the slope of the regression line varied from 1.042 to 1.556. Significantly higher results from the microbiological assay were probably due to the presence of microbiologically active metabolites. We conclude that HPLC is the more specific method of determination. The described methods were applied for pharmacokinetic studies and therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942623     DOI: 10.1515/cclm.1986.24.5.325

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  7 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.

Authors:  A Lubasch; I Keller; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection.

Authors:  S Leitzke; W Bucke; K Borner; R Müller; H Hahn; S Ehlers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Oral vs intravenous antibiotic prophylaxis in elective laparoscopic cholecystectomy: an exploratory trial.

Authors:  Urte Zurbuchen; Joerg-P Ritz; Kai S Lehmann; Joern Groene; Majid Heidari; Heinz J Buhr; Christoph-T Germer
Journal:  Langenbecks Arch Surg       Date:  2007-12-18       Impact factor: 3.445

6.  Urinary excretion of ciprofloxacin after administration of extended release tablets in healthy volunteers. Swellable drug-polyelectrolyte matrix versus bilayer tablets.

Authors:  M L Guzmán; C B Romañuk; M F Sanchez; L C Luciani Giacobbe; L P Alarcón-Ramirez; F D Battistini; F L Alovero; A F Jimenez-Kairuz; R H Manzo; María Eugenia Olivera
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

7.  A novel validated stability indicating high performance liquid chromatographic method for estimation of degradation behavior of ciprofloxacin and tinidazole in solid oral dosage.

Authors:  Bhupendrasinh K Vaghela; Surendra Singh Rao
Journal:  J Pharm Bioallied Sci       Date:  2013-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.